Deutsche Bank’s Aligos Therapeutics ALGS Stock Holding History

Deutsche Bank’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,852	Closed	-$69.2K	–	3702
2023 Q2	$69.2K	Hold	2,852	–	–	﹤0.01%	3404
2023 Q1	$62.3K	Hold	2,852	–	–	﹤0.01%	3495
2022 Q4	$67.9K	Hold	2,852	–	–	﹤0.01%	3483
2022 Q3	$78K	Hold	2,852	–	–	﹤0.01%	3443
2022 Q2	$86K	Sell	2,852 -470	-14%	-$16K	﹤0.01%	3584
2022 Q1	$179K	Sell	3,322 -54	-2%	-$4.32K	﹤0.01%	3331
2021 Q4	$1M	Buy	3,376 +26	+0.8%	+$9.48K	﹤0.01%	2436
2021 Q3	$1.3M	Sell	3,350 -510	-13%	-$202K	﹤0.01%	2445
2021 Q2	$1.97M	Buy	3,860 +240	+7%	+$153K	﹤0.01%	2237
2021 Q1	$2.06M	Buy	3,620 +3,337	+1,179%	+$2.22M	﹤0.01%	2152
2020 Q4	$196K	Buy	+283	New	+$138K	﹤0.01%	3478

Other funds holding ALGS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Deutsche Bank's ALGS Position: Q3 2023 in Review

Deutsche Bank sold out of Aligos Therapeutics (ALGS) in Q3 2023, closing a stake of 2,852 shares — an estimated $69.2K sold.

Deutsche Bank first reported a position in ALGS in Q4 2020 and held it in 11 quarters. The position peaked at $2.06M in Q1 2021. 35 funds tracked by Wall St. Rank hold ALGS as of Q3 2023.

Deutsche Bank reported no remaining Aligos Therapeutics position as of Q3 2023 after selling out during the quarter.
Deutsche Bank sold 2,852 Aligos Therapeutics shares in Q3 2023, an estimated $69.2K.
Deutsche Bank first reported a position in Aligos Therapeutics in Q4 2020 and held it in 11 quarters.
Deutsche Bank's Aligos Therapeutics position peaked at $2.06M in Q1 2021.
35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2023.

Based on Deutsche Bank's 13F filing for Q3 2023, filed 9 Nov 2023.